BBHVanEck Biotech ETF
Seeks to replicate the price and yield performance of the MVIS US Listed Biotech 25 Index.
By VanEck · Launched 2011
Annual Cost
0.35%
#1,644 of 5,854 · low cost
Fund Size
$396M
#1,787 of 5,854 · large
Return (1Y)Goal
+26.1%
Track Record
14 years
#933 of 5,854 · established
Performance
Total-return NAV · USDGrowth of $10,000
$11,209+12.1%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Mid
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
MVIS US Listed Biotech 25 Index
What it actually holds
By weightConcentration
Top 10 holdings = 70.8% of fundconcentrated
Gilead Sciences Inc
14.6%
Amgen Inc
14.5%
Vertex Pharmaceuticals Inc
8.1%
Regeneron Pharmaceuticals Inc
7.5%
Argenx SE
5.3%
Insmed Inc
4.6%
IQVIA Holdings Inc
4.3%
Alnylam Pharmaceuticals Inc
4.1%
Natera Inc
4.0%
United Therapeutics Corp
3.8%
Asset allocation
Stocks
99.9%
Cash
0.1%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
19.5%Moderate
Year-on-year price swings
Max drawdown
-39.9%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.36Below average
Sortino (3Y)
0.51Moderate downside risk
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks to replicate the price and yield performance of the MVIS US Listed Biotech 25 Index.
- Strategy
- Uses a passive investment approach to replicate the MVIS US Listed Biotech 25 Index by investing at least 80% of total assets in common stocks and depositary receipts of U.S. biotechnology companies. The Fund may concentrate its investments in the biotechnology industry, which includes companies with market capitalizations between approximately $9.16 billion and $176.26 billion.
- Inception date
- December 20, 2011
- Fund family
- VanEck
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at BBH. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-03